RVMD – Revolution Medicines, Inc.
Revolution Medicines, Inc.RVMD
$180.70Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $39,084,019,712.00
EPSttm : -9.13
Revolution Medicines, Inc.
$180.70
6.40%$12.36
RVMD — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.71
Margin Of Safety %
Put/Call OI Ratio
0.78
EPS Next Q Diff
0.94
EPS Last/This Y
-2.35
EPS This/Next Y
4.9
Price
180.66
Target Price
275.8
Analyst Recom
1.08
Performance Q
-10.54
Upside
-276.3%
Beta
1.43
Ticker: RVMD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | RVMD | 188.54 | 0.70 | 2.98 | 50167 |
| 2026-10-14 | RVMD | 193.75 | 0.76 | 0.33 | 51891 |
| 2026-10-15 | RVMD | 189.48 | 0.75 | 0.54 | 52286 |
| 2026-10-16 | RVMD | 178.02 | 0.75 | 1.71 | 52449 |
| 2026-10-19 | RVMD | 182 | 0.96 | 0.19 | 54989 |
| 2026-10-20 | RVMD | 197.24 | 0.93 | 0.17 | 56268 |
| 2026-10-21 | RVMD | 194.22 | 1.02 | 0.58 | 53428 |
| 2026-10-22 | RVMD | 184.7 | 1.02 | 0.14 | 53483 |
| 2026-10-23 | RVMD | 186.95 | 1.00 | 0.87 | 54077 |
| 2026-10-26 | RVMD | 183.84 | 0.99 | 0.45 | 54350 |
| 2026-10-27 | RVMD | 186.33 | 0.98 | 0.14 | 55118 |
| 2026-10-28 | RVMD | 188.74 | 0.99 | 0.16 | 54889 |
| 2026-10-29 | RVMD | 190.28 | 0.99 | 15.32 | 54940 |
| 2026-10-30 | RVMD | 191.48 | 0.79 | 1.47 | 49707 |
| 2026-11-02 | RVMD | 188.18 | 0.79 | 0.18 | 49784 |
| 2026-11-03 | RVMD | 194.35 | 0.79 | 0.23 | 49827 |
| 2026-11-04 | RVMD | 199.7 | 0.80 | 1.42 | 49792 |
| 2026-11-05 | RVMD | 177.65 | 0.79 | 0.22 | 50556 |
| 2026-11-06 | RVMD | 192.13 | 0.80 | 0.21 | 51091 |
| 2026-11-09 | RVMD | 200.33 | 0.78 | 0.18 | 52023 |
| 2026-11-10 | RVMD | 193.16 | 0.79 | 0.36 | 51867 |
| 2026-11-11 | RVMD | 180.65 | 0.78 | 0.19 | 52167 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | RVMD | 188.48 | -48.3 | - | -9.62 |
| 2026-10-14 | RVMD | 193.69 | -48.1 | - | -9.60 |
| 2026-10-15 | RVMD | 189.46 | -48.1 | - | -9.60 |
| 2026-10-16 | RVMD | 178.07 | -48.4 | - | -9.60 |
| 2026-10-19 | RVMD | 182.08 | -48.4 | - | -9.60 |
| 2026-10-20 | RVMD | 182.08 | -48.4 | - | -9.60 |
| 2026-10-21 | RVMD | 196.59 | -48.2 | - | -9.59 |
| 2026-10-22 | RVMD | 187.69 | -48.2 | - | -9.59 |
| 2026-10-23 | RVMD | 187.03 | -48.2 | - | -9.59 |
| 2026-10-26 | RVMD | 183.84 | -48.9 | - | -9.59 |
| 2026-10-27 | RVMD | 186.28 | -47.9 | - | -9.58 |
| 2026-10-28 | RVMD | 188.71 | -47.9 | - | -9.58 |
| 2026-10-29 | RVMD | 190.26 | -47.9 | - | -9.58 |
| 2026-10-30 | RVMD | 191.32 | -47.9 | - | -9.58 |
| 2026-11-02 | RVMD | 188.29 | -47.9 | - | -9.58 |
| 2026-11-04 | RVMD | 199.50 | -47.9 | - | -9.58 |
| 2026-11-05 | RVMD | 177.92 | -47.9 | - | -9.58 |
| 2026-11-06 | RVMD | 192.18 | -47.9 | - | -9.58 |
| 2026-11-09 | RVMD | 200.25 | -47.9 | - | -9.58 |
| 2026-11-10 | RVMD | 193.05 | 30.7 | - | -8.60 |
| 2026-11-11 | RVMD | 180.66 | 38.1 | - | -8.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | RVMD | -3.01 | 6.53 | 6.18 |
| 2026-10-14 | RVMD | -3.01 | 6.53 | 6.18 |
| 2026-10-15 | RVMD | -3.01 | 6.53 | 6.18 |
| 2026-10-16 | RVMD | -3.01 | 6.53 | 6.18 |
| 2026-10-19 | RVMD | -2.47 | 6.54 | 6.18 |
| 2026-10-20 | RVMD | -2.47 | 6.54 | 6.18 |
| 2026-10-21 | RVMD | -2.47 | 6.54 | 6.18 |
| 2026-10-22 | RVMD | -2.47 | 6.54 | 6.18 |
| 2026-10-23 | RVMD | -2.47 | 6.54 | 6.18 |
| 2026-10-26 | RVMD | -2.47 | 7.42 | 6.18 |
| 2026-10-27 | RVMD | -2.47 | 7.42 | 6.70 |
| 2026-10-28 | RVMD | -2.47 | 7.42 | 6.70 |
| 2026-10-29 | RVMD | -2.48 | 7.42 | 6.70 |
| 2026-10-30 | RVMD | -2.47 | 7.42 | 6.70 |
| 2026-11-02 | RVMD | -2.47 | 7.31 | 6.70 |
| 2026-11-03 | RVMD | -2.47 | 7.31 | 6.70 |
| 2026-11-05 | RVMD | -2.47 | 7.31 | 6.70 |
| 2026-11-06 | RVMD | -2.47 | 7.31 | 6.70 |
| 2026-11-09 | RVMD | -2.45 | 5.77 | 6.64 |
| 2026-11-10 | RVMD | -2.45 | 5.77 | 6.64 |
| 2026-11-11 | RVMD | -2.45 | 5.77 | 6.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.9
Avg. EPS Est. Current Quarter
-1.15
Avg. EPS Est. Next Quarter
-0.96
Insider Transactions
-2.45
Institutional Transactions
5.77
Beta
1.43
Average Sales Estimate Current Quarter
426
Average Sales Estimate Next Quarter
462
Fair Value
Quality Score
29
Growth Score
38
Sentiment Score
77
Actual DrawDown %
19.5
Max Drawdown 5-Year %
-55.7
Target Price
275.8
P/E
Forward P/E
PEG
P/S
197.83
P/B
16.27
P/Free Cash Flow
EPS
-9.1
Average EPS Est. Cur. Y
-8.3
EPS Next Y. (Est.)
-3.39
Target Price Estimates Raised
7
Target Price Estimates Lowered
Profit Margin
-946.82
Relative Volume
1.57
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-84.7
EPS 1 7Days Diff
1.3
EPS 1 30Days Diff
1.32
EBIT Estimation
◆
RVMD
Healthcare
$180.70
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.7
Range 1M
13.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-43%
EPS NY
65.3%
52W%
72.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+52.6% upside
Upside
+52.6%
Quality
29
RVMD — P/E HistoricalBiotechnology
Revolution Medicines, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 883
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD
Latest News
—
Caricamento notizie per RVMD…
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading